Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
Provided By PR Newswire
Last update: Oct 7, 2025
Presentation to highlight advancements in Hoth's clinical pipeline, including
HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program
targeting KIT-driven tumors
